Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Tytuł pozycji:

Brief Report: High Need to Switch cART or Comedication With the Initiation of DAAs in Elderly HIV/HCV-Coinfected Patients.

Tytuł:
Brief Report: High Need to Switch cART or Comedication With the Initiation of DAAs in Elderly HIV/HCV-Coinfected Patients.
Autorzy:
Smolders EJ; Department of Pharmacy, Radboud Institute of Health Sciences (RIHS) and Radboud university medical center, Nijmegen, the Netherlands; †HIV Monitoring Foundation, Amsterdam, the Netherlands; ‡Department of Pharmacy, University Medical Center Utrecht, Utrecht, the Netherlands; §Department of Internal Disease and Infectious Diseases, Radboud university medical center, Nijmegen, the Netherlands; ‖Department of Internal Medicine and Infectious Diseases, University Medical Center, Utrecht, the Netherlands; ¶Department of Internal Medicine and Infectious Diseases, OLVG, Amsterdam, the Netherlands; #Department of Internal Medicine and Infectious Diseases, Erasmus MC University Medical Center, Rotterdam, the Netherlands; **Academic Medical Center, Division of Infectious Diseases, and Center for Infection and Immunity Amsterdam (CINIMA), Amsterdam, the Netherlands; and ††Department of Global Health and Amsterdam Institute for Global Health and Development, Academic Medical Center of the University of Amsterdam, Amsterdam, the Netherlands.
Smit C
T M M de Kanter C
Dofferiiof ASM
Arends JE
Brinkman K
Rijnders B
van der Valk M
Reiss P
Burger DM
Źródło:
Journal of acquired immune deficiency syndromes (1999) [J Acquir Immune Defic Syndr] 2017 Oct 01; Vol. 76 (2), pp. 193-199.
Typ publikacji:
Journal Article
Język:
English
Imprint Name(s):
Original Publication: Hagerstown, MD : Lippincott Williams & Wilkins, Inc., c1999-
MeSH Terms:
Anti-Retroviral Agents/*therapeutic use
Antiviral Agents/*therapeutic use
Coinfection/*drug therapy
HIV Infections/*drug therapy
Hepatitis C/*drug therapy
Adult ; Aged ; Aged, 80 and over ; Amides ; Benzofurans/therapeutic use ; Carbamates ; Combined Modality Therapy ; Cross-Sectional Studies ; Cyclopropanes ; Drug Interactions ; Drug Therapy, Combination ; HIV/drug effects ; Hepacivirus/drug effects ; Humans ; Imidazoles/therapeutic use ; Middle Aged ; Quinoxalines/therapeutic use ; Retrospective Studies ; Ritonavir/therapeutic use ; Sulfonamides ; Young Adult
Substance Nomenclature:
0 (Amides)
0 (Anti-Retroviral Agents)
0 (Antiviral Agents)
0 (Benzofurans)
0 (Carbamates)
0 (Cyclopropanes)
0 (Imidazoles)
0 (Quinoxalines)
0 (Sulfonamides)
4O2AB118LA (grazoprevir)
632L571YDK (elbasvir)
O3J8G9O825 (Ritonavir)
Entry Date(s):
Date Created: 20170914 Date Completed: 20170925 Latest Revision: 20220909
Update Code:
20240104
DOI:
10.1097/QAI.0000000000001488
PMID:
28902678
Czasopismo naukowe
Background: To describe the use of nonantiretroviral comedication and combination antiretroviral therapy (cART) in patients coinfected with HIV/hepatitis C virus (HCV) and to predict the potential for drug-drug interactions (DDIs) with direct-acting antivirals (DAAs) against HCV.
Methods: This is a retrospective, cross-sectional study, using the Dutch, nationwide ATHENA observational HIV cohort database. All patients with a known HIV/HCV coinfection on January 1, 2015, were included. Comedication and cART registered in the database were listed. The potential for DDIs between DAAs and comedication/cART were predicted using http://hep-druginteractions.org. DDIs were categorized as: (1) no clinically relevant DDI; (2) possible DDI; (3) contraindication; or (4) no information available.
Results: We included 777 patients of whom 488 (63%) used nonantiretroviral comedication. At risk for a category 2/3 DDI with nonantiretroviral comedications were 299 patients (38%). Most DDIs were predicted with paritaprevir/ritonavir, ombitasvir ± dasabuvir (47% of the drugs) and least with grazoprevir/elbasvir (11% of the drugs). Concerning cART, daclatasvir/sofosbuvir is the most favorable combination as no cART is contraindicated with this combination. In genotype 1/4 patients, grazoprevir/elbasvir is least favorable as 75% of the patients must alter their cART.
Conclusions: This study showed that comedication use in the aging HIV/HCV population is frequent and diverse. There is a high potential for DDIs between DAAs and comedication/cART.

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies